BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19775641)

  • 1. Therapy of diffuse large B-cell lymphomas.
    Pfreundschuh M
    Eur J Cancer; 2009 Sep; 45 Suppl 1():386-7. PubMed ID: 19775641
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-Hodgkin's lymphoma (diffuse large B cell lymphoma).
    Copson E
    Clin Evid; 2005 Jun; (13):1-18. PubMed ID: 16135258
    [No Abstract]   [Full Text] [Related]  

  • 3. Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains.
    Yahalom J
    J Clin Oncol; 2010 Sep; 28(27):4105-7. PubMed ID: 20713874
    [No Abstract]   [Full Text] [Related]  

  • 4. CHOP and rituximab in elderly patients.
    Portlock CS
    Curr Oncol Rep; 2002 Sep; 4(5):414. PubMed ID: 12162916
    [No Abstract]   [Full Text] [Related]  

  • 5. CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma.
    Fisher RI
    Important Adv Oncol; 1990; ():217-25. PubMed ID: 2182520
    [No Abstract]   [Full Text] [Related]  

  • 6. Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large B-cell lymphomas, leg type, in elderly patients.
    Guyot A; Ortonne N; Valeyrie-Allanore L; Bagot M
    Arch Dermatol; 2010 Jan; 146(1):89-91. PubMed ID: 20083704
    [No Abstract]   [Full Text] [Related]  

  • 7. The clinician's decision of whether CHOP chemotherapy should be standard therapy for treatment of patients with diffuse histiocytic lymphoma.
    Connors JM
    Important Adv Oncol; 1990; ():227-33. PubMed ID: 2182521
    [No Abstract]   [Full Text] [Related]  

  • 8. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy.
    Navarro JT; Lloveras N; Ribera JM; Oriol A; Mate JL; Feliu E
    Haematologica; 2005 May; 90(5):704-6. PubMed ID: 15921395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Testoni M; Kwee I; Greiner TC; Montes-Moreno S; Vose J; Chan WC; Chiappella A; Baldini L; Ferreri AJ; Gaidano G; Mian M; Zucca E; Bertoni F
    Br J Haematol; 2011 Oct; 155(2):274-7. PubMed ID: 21488860
    [No Abstract]   [Full Text] [Related]  

  • 11. Front-line management of diffuse large B cell lymphoma.
    Cabanillas F
    Curr Opin Oncol; 2010 Nov; 22(6):642-5. PubMed ID: 20811278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard treatment of advanced-stage diffuse large B-cell lymphoma.
    Coiffier B
    Semin Hematol; 2006 Oct; 43(4):213-20. PubMed ID: 17027655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inappropriate antidiuretic hormone production in diffuse large B-cell lymphoma.
    Kobayashi K; Yokote T; Akioka T; Takubo T; Tsuji M; Hanafusa T
    Br J Haematol; 2008 Oct; 143(1):2. PubMed ID: 18513282
    [No Abstract]   [Full Text] [Related]  

  • 14. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
    Miles SA; McGratten M
    J Clin Oncol; 2005 Jan; 23(1):247-8. PubMed ID: 15625386
    [No Abstract]   [Full Text] [Related]  

  • 15. A paraumbilical lymphomatous mass.
    Burcheri S; Arcaini L
    Eur J Haematol; 2006 Aug; 77(2):180. PubMed ID: 16856915
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab.
    Grange F; Maubec E; Bagot M; Beylot-Barry M; Joly P; Dalle S; Delaporte E; Dereure O; Bachelez H; Vergier B; Petrella T; D'Incan M
    Arch Dermatol; 2009 Mar; 145(3):329-30. PubMed ID: 19289772
    [No Abstract]   [Full Text] [Related]  

  • 17. [Prognostic impact of bone marrow involvement (BMI) and therapies in diffuse large B cell lymphoma].
    Yi SH; Xu Y; Zou DH; An G; Zhao YZ; Qi JY; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):307-12. PubMed ID: 19799125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse large B-cell lymphoma with fibrillary matrix.
    Dargent JL; Meiers I; Lespagnard L; Ma Y; Dehou MF; Verhest A
    Diagn Cytopathol; 2002 Oct; 27(4):223-6. PubMed ID: 12357500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International prognostic index-based outcomes for diffuse large B-cell lymphomas.
    Wilder RB; Rodriguez MA; Medeiros LJ; Tucker SL; Ha CS; Romaguera JE; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2002 Jun; 94(12):3083-8. PubMed ID: 12115338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases.
    Oprea C; Cainap C; Azoulay R; Assaf E; Jabbour E; Koscielny S; Lapusan S; Vanel D; Bosq J; Ribrag V
    Br J Haematol; 2005 Nov; 131(4):468-71. PubMed ID: 16281936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.